Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide is a synthetic small molecule belonging to the benzenesulfonamide class. It features a sulfonamide group attached to a benzene ring, which is further substituted with an amino linkage to a chlorinated pyrazine moiety. This compound has been studied as an experimental agent and is known primarily for its activity as an inhibitor of cyclin-dependent kinase 2 (CDK2), suggesting potential utility in modulating cell cycle progression. However, it has not been approved for clinical use in humans or animals and remains at the experimental stage[1][2][3]. Some structurally related compounds are used as sulfonamide antibiotics in veterinary medicine, but this specific molecule's primary documented mechanism is CDK2 inhibition[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide.